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Abstract
Circular RNAs (circRNAs) are a class of endogendous RNAs that form a covalently closed continuous loop and
exist extensively in mammalian cells. Majority of circRNAs are conserved across species and often show tissue/
developmental stage-specific expression. CircRNAs were first thought to be the result of splicing error; however,
subsequent research shows that circRNAs can function as microRNA (miRNA) sponges and regulate splicing and
transcription. Emerging evidence shows that circRNAs possess closely associated with human diseases, especially
cancers, and may serve as better biomarkers. After miRNA and long noncoding RNA (lncRNA), circRNAs are
becoming a new hotspot in the field of RNA of cancer. Here, we review biogenesis and metabolism of circRNAs,
their functions, and potential roles in cancer.
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Background
Noncoding RNAs (ncRNA) can be categorized into two
subclasses, namely housekeeper ncRNAs (ribosomal
RNA (rRNA), tRNA, small nuclear RNA (snRNA),
snoRNA) and regulatory ncRNAs. Regulatory ncRNAs have
been classified by length as follows: small noncoding RNAs
(<200 bp), which includes microRNAs (miRNAs), snRNAs,
piRNAs, siRNAs, and others, and long ncRNAs (lncRNAs)
(>200 bp). Among the lncRNAs, circular RNAs (circRNAs)
have recently emerged as a new class of endogenous RNAs
that form a covalently closed continuous loop without 5′
caps and 3′ tails and exist extensively in mammalian cells.
CircRNA was first found more than 20 years ago from
identifying spliced transcripts of a candidate tumor sup-
pressor gene by Nigro et al. in 1991 [1]. However, this novel
type of RNA product has been thought to result from spli-
cing errors with no function [2] and paid little attention
over the next decade. Because of rapid advances in high-
throughput sequencing, a large number of circRNAs have
been discovered and several properties were uncovered.
Firstly, circRNAs seem to be specifically expressed in
tissues or developmental stage [3]. Secondly, circRNAs
were more stable than associated linear mRNAs in vivo for
their resistance to RNase activity [3, 4]. Thirdly, circRNAs
from >14% of actively transcribed genes in human fibro-
blasts and in some cases the abundance of circular mole-
cules exceeded that of associated linear mRNA by >10-fold
[4]. Also, they are predominately cytoplasmic, but some
seemed to be enriched in the nucleus [3–5].
Biogenesis of circRNAs
CircRNAs have multiple origins. The majority of them
are originated from exons of coding regions and the rest
from 3′ UTR, 5′ UTR, introns, intergenic regions, and
antisense RNAs [6]. Different from canonical splicing of
linear RNAs, a single gene locus can produce various
circRNAs through alternative back-splice site selection
[7]. CircRNAs can be generated by both canonical and
noncanonical splicing (Fig. 1). Up to now, three types of
circRNAs have been identified by high-throughput se-
quencing: exonic circRNAs [4], circular intronic RNAs
(ciRNAs) [8], and retained-intron circRNAs or ElciRNAs
[9]. Exonic circRNAs account for over 80% of identified
circRNAs. However, the mechanisms of biogenesis of
circRNAs remain unclear. In 2013, Jeck et al. proposed
two models of exonic circRNA formation [4]. One model
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is named “lariat-driven circularization,” and the other one
is named “intronpairing-driven circularization”. It is
widely accepted that back-splicing occurs in reversed
orientation that connects a downstream 5′ splice site to
an upstream 3′ splice site to produce circRNAs [7]. Ivanov
et al. reported that circRNA formation mechanism de-
pends on the RNA-editing enzyme adenosine deaminase
acting on RNA (ADAR) [10]. Additionally, researchers re-
ported that the RNA-binding quaking (QKI) could facili-
tate circRNA biogenesis during epithelial to mesenchymal
transition (EMT) [11]. Recently, Gao et al. explored
internal components including alternative splicing events
(AS) such as exon skipping (ES), intron retention (IR), and
alternative 5′ or 3′ splicing site (A5SS and A3SS) within
circRNAs [12]. They demonstrated that frequency of AS
events varies in different cell types, which suggest their
potential roles in gene regulation.
Biological functions of circRNAs
CircRNAs can function as miRNA sponges, RNA-
binding protein (RBP) sponges, and regulators of
Fig. 1 Canonical and noncanonical splicing of circRNA. a mRNA and ciRNA by canonical splicing. b circRNA by direct back splicing. c ciRNA by
back splicing. d circRNA and EIciRNA by RBP-driven circularization. Abbreviations: ciRNA circular intronic RNA, circRNA exonic circular RNA, ElciRNA
exon-intron circular RNA, RBP RNA-binding protein
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transcription, and few circRNAs can be translated into
proteins/peptides (Fig. 2).
miRNA sponge
MiRNAs are an abundant class of short (~22 nt) non-
coding RNAs that posttranscriptionally regulate gene ex-
pression via direct base pairing to target sites within
mRNAs [13]. As the competitive endogenous RNAs
(ceRNAs), circRNAs can compete for miRNA-binding
sites. Thus, the presence of miRNAs sponges, circRNAs,
can affect miRNA activities [3, 14]. For example, a cir-
cRNA named ciRS-7 or CDR1as (circular RNA sponge
for miR-7 or antisense to the cerebellar degeneration-
related protein 1 transcript) contains more than 70 se-
lectively conserved miRNA target sites, and it is highly
associated with Argonaute (AGO) proteins in a miR-7-
dependent manner [14].
Regulators of transcription
Previous studies have provided evidence that circRNAs
form a large number of posttranscriptional regulators
[3]. Zhang and colleagues uncovered that circRNAs
could regulate the expression of parental genes. They
discovered that circRNAs are abundant in the nucleus
with little enrichment for miRNA target sites, and
knockdown of ciRNAs could lead to the reduced expres-
sion of their parental genes [3, 8]. Moreover, researchers
reported after further studies that ElciRNAs, such as
circEIF3J and circPAIP2, interact with U1 small nuclear
ribonucleoprotein particle (U1snRNP) RNA and poly-
merase II (Pol II) and can enhance the transcription of
their parental genes in a cis-acting manner [15]. The
similar trend was also observed in circRNA PAIP2 and
its parental gene [16].
From the above, we speculate that transcription activa-
tion may be a general function of circular RNAs
containing intronic sequences, such as ciRNAs and
EIciRNAs, and their regulatory functions may explain
the abundance of ciRNAs and EIciRNAs in the nucleus.
Translation of circRNAs into protein/peptide
As some circRNAs carry open reading frames, one may
speculate that they are translated into peptides. Early in
1998, Perriman et al. reported that a circular mRNA
containing a simple green fluorescent protein (GFP)
open reading frame could direct GFP expression in
Escherichia coli [16]. Subsequently, AbouHaidar et al.
discovered a circRNA (220 nt) of the virusoid associated
with rice yellow mottle virus can code for a 16-kD pro-
tein [17]. It was shown that peptides can be translated
from circRNAs in vitro [18] or in vivo [16], only when
the RNAs contain internal ribosome entry site elements
(IRES) [18] or prokaryotic ribosome-binding sites [16].
Recently, a circRNA database, named circRNADb, con-
taining 32,914 human exonic circRNAs was established
[19]. It provided detailed information of the circRNAs,
including genome sequence, IRES, and open reading
frame (ORF), for users to predict the translatability of
certain circRNAs. However, there is no experimental evi-
dence to prove that spliceosome-generated ecircRNAs
can serve as mRNAs.
Besides serving as miRNA sponge and transcription
regulator, circRNAs certainly serve as mRNA traps via
Fig. 2 Overview of the four molecular functions of circRNA. a circRNAs can interact with miRNAs, acting as “sponges”. b circRNA have a direct
role in translation. c ciRNA can enhance the expression of parent genes; ElciRNA can also enhance the expression of parental genes with U1
snRNP and Pol II. d circRNA can generate functional proteins. Abbreviations: circRNAs circular RNAs, miRNA microRNA, ciRNA circular intronic
RNA, Pol II polymerase II, ElciRNA exon-intron circular RNA, U1 snRNP U1 small nuclear ribonucleoprotein particle, mRNA messenger RNA, rRNA
ribosome RNA
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sequestering the translation start site to regulate protein
expression [20].
Metabolism of circRNAs
CircRNAs are highly stable although the mechanisms by
which cells degrade and/or clear circRNAs are unknown.
Recently, researchers raised the possibility that cells can
eliminate circRNAs via released vesicles such as exo-
somes and microvesicles when they reported secretion
of multiple circRNAs from three different cell lines [21].
The result showed that circRNAs examined are enriched
over their linear counterparts within extracellular vesicle
(EV) preparations when compared to the producing
cells, which suggests that expulsion from cells into
extracellular space by EV release can be a mechanism by
which cells reduce circRNAs.
CircRNAs in cancer
Emerging evidence shows that circRNAs possess closely
associated with human diseases, especially cancers. A re-
port revealed that hundreds of circRNAs are more abun-
dant in blood than corresponding linear mRNAs, which
suggests that circRNAs could be used as new biomarkers
in standard clinical blood samples [22]. Here, we discuss
recent discoveries that implicate aberrant circRNAs in
cancer (Table 1).
CircRNAs and gastric cancer
A report showed that hsa_circ_002059, a typical circular
RNA, was found to be significantly downregulated in
gastric cancer tissues compared with paired adjacent
nontumor tissues. Furthermore, its levels in plasma were
found significantly different between postoperative
gastric cancer patients and preoperative gastric cancer
patients. Importantly, that lower expression levels were
significantly correlated with distal metastasis, tumor
node metastasis (TNM) stage, gender, and age. In con-
clusion, these results suggested that circRNAs, hsa_
circ_002059, may be a potential stable biomarker for the
diagnosis of gastric carcinoma [23].
This study clearly demonstrated the clinical implica-
tions of hsa_circ_002059 as a biomarker, since its ex-
pression is able to distinguish normal gastric adjacent
mucosa from gastric cancer tissue. Further, this circRNA
may also be used as a molecular biomarker in evaluating
the effectiveness of gastric resection.
CircRNAs and colorectal cancer
Wang et al. investigated the circRNA expression in
colorectal cancer (CRC), hsa_circ_001988, was se-
lected from next-generation sequence data base for
further investigation. The findings showed that the
expression of hsa_circ_001988 was decreased in
tumor tissues, which suggests that hsa_circ_001988
may be a novel treatment target and a potential bio-
marker of colorectal cancer [24].
Another report demonstrated that circRNAs were
enriched in serum exosomes and could distinguish CRC
from healthy controls [6]. Additionally, the abundance of
tumor-derived serum exosomal circRNAs (exo-circRNAs)
Table 1 Summary of circRNAs in cancer
Cancer name CircRNA name Expression level Scope Sample Intersection molecules and/
or pathway
References
Bladder carcinoma circTCF25 Up Bladder carcinoma
vs normal
Tissues (n = 40) miR-103a-3p,miR-107;
circTCF25-miR-103a-3p/
miR-107-CDK6
Zhong et al. [28]
cSCC hsa_circ_0035381 Up cSCC vs normal Tissues (n = 12) hsa-miR-124-5p,hsa-miR-9-5p Sand et al. [32]
hsa_circ_0022383 Down hsa-miR-124-5p
ESCC cir-ITCH Down ESCC vs normal Tissues (n = 684) miR-7, miR-17, and miR-214;
Wnt/β-catenin pathway
Li et al. [34]
Gastric cancer has_circ_002059 Down Gastric cancer
vs normal
Tissues (n = 101) – Li et al. [23]
Plasma (n = 36)
CRC hsa_circ_001988 Down CRC vs normal Tissues (n = 31) – Wang et al. [24]
cir-ITCH Down CRC vs normal Tissues (n = 45) Wnt/β-catenin pathway Huang et al. [25]
HCC hsa_circ_0001649 Down HCC vs normal Tissues (n = 89) – Qin et al. [26]
LSCC hsa_circ_104912 Down LSCC vs normal Tissues (n = 52) – Xuan et al. [27]
hsa_circ_100855 Up
APL f-circRNA – f-circRNA-expressing
vas normal
Cells PI3K and MAPK signal
transduction pathways
Guarnerio et al. [29]
Notes: Up upregulated, down downregulated
Abbreviations: circRNAs circular RNAs, cSCC cutaneous squamous cell carcinoma, ESCC esophageal squamous cell carcinoma, CRC colorectal cancer, HCC
hepatocellular carcinoma, LSCC laryngeal squamous cell cancer, APL acute promyelocytic leukemia
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in serum of xenografted mice was correlated with tumor
mass, which indicates that the exo-circRNAs may have an
extracellular function and significant translational poten-
tial as a circulating biomarker for cancer diagnosis. Fur-
thermore, it is also found that cir-ITCH expression was
typically downregulated in CRC, and cir-ITCH could in-
crease the level of ITCH, which is involved in the inhib-
ition of the Wnt/β-catenin pathway. Thus, cir-ITCH may
play a role in CRC by regulating the Wnt/β-catenin path-
way [25]. Studies cited above illustrate that circRNAs are
promising biomarkers for CRC.
CircRNAs and hepatocellular carcinoma
Hsa_circ_0001649 expression was significantly downreg-
ulated in hepatocellular carcinoma (HCC) tissues based
on an analysis of 89 paired samples of HCC and adjacent
liver tissues. The findings indicate that hsa_circ_0001649
might serve as a new potential biomarker for HCC
and may play a role in tumorigenesis and metastasis
of HCC [26].
CircRNAs and laryngeal cancer
Reseachers found significant upregulation (n = 302) or
downregulation (n=396) of 698 circRNAs in laryngeal
squamous cell cancer (LSCC) tissues via microarray ana-
lysis of four paired LSCC tissues. They further reported
hsa_circRNA_100855 as the most upregulated circRNA,
and their results showed that hsa_circRNA_100855
expression was significantly higher in LSCC than in
the adjacent nonneoplastic tissues [27]. Overall, the
data suggest that circRNAs play an important role in
the tumorigenesis of LSCC and may function as novel
and stable biomarkers for the diagnosis and progress
of LSCC.
CircRNAs and bladder carcinoma
CircRNA profiling and circRNA/miRNA interactions
were first studied in bladder cancer, and researchers
demonstrated that overexpression of circTCF25 could
downregulate miR-103a-3p and miR-107, increase
cyclin-dependent kinase 6 (CDK6) expression, and pro-
mote proliferation and migration in vitro and in vivo.
Their work laid the foundation to investigate the func-
tions of circRNAs in cancers. The data also suggested
that circTCF25 was a new promising marker for
bladder cancer [28].
CircRNAs and acute promyelocytic leukemia
Researchers showed that well-established cancer-associated
chromosomal translocations gave rise to fusion circRNAs
(f-circRNA) that were produced from transcribed exons of
distinct genes affected by the translocations. And then, they
analyzed the presence of f-circRNA (both f-circPR and f-
circM9) in the acute promyelocytic leukemia (APL)-derived
leukemic cell line NB4. The data support the notion that f-
circRNA, when coupled with other oncogenic stimuli, plays
an active role in favoring leukemia progression in vivo [29].
Alhasan et al. found that circRNAs are enriched in human
platelets 17- to 188-fold relative to nucleated tissues. As
circRNAs are tolerated to degradation by exonucleases,
their abundance relative to linear RNAs can be used as a
marker in place of mRNA stability in the absence of
transcription [30]. Previous research showed that mRNA
sequencing of tumor-educated blood platelets could distin-
guish cancer patients from healthy population with 96% ac-
curacy, and the location of the primary tumor was correctly
identified with 71% accuracy across six different tumor
types [31]. These results suggest that circRNAs and their
quantity alteration in blood platelets may play a role in the
diagnosis and treatment of tumor.
Other cancers
In a recent report, a total of 322 circRNAs were differen-
tially expressed in cutaneous squamous cell carcinoma
(cSCC) and 1603 miRNA response elements (MREs) were
identified in the differentially expressed circRNAs. Results
showed that circRNAs are differentially expressed in cSCC
and are involved in tumor formation by interfering with
cSCC relevant miRNAs via miRNA sequence complemen-
tary MREs participating in epigenetic control [32].
Another study explored that the circRNA expression sig-
natures of PDAC are dysregulated via microarray plat-
form. The findings indicate that circRNAs can be involved
in the initiation and progression of PDAC [33]. Li et al.
found that cir-ITCH expression was usually low in
esophageal squamous cell carcinoma (ESCC) compared to
the peritumoral tissue. As sponge of miR-7, miR-17, and
miR-214, cir-ITCH might increase the level of ITCH,
which hyper expression promotes ubiquitination and deg-
radation of phosphorylated Dvl2, thereby inhibiting the
Wnt/β-catenin pathway [34].
CDR1as contains more than 70 selectively conserved
target sites of miR-7, and emerging evidence indicates that
miR-7 can directly downregulate oncogenes. Thereby, the
CDR1as/miRNA axis is likely involved in cancers such as
melanoma [35], breast cancer [36], gliocytoma [37], gastric
cancer [38], liver cancer [39], and non-small cell lung can-
cer (NSCLC) [40]. It would be interesting to uncover the
function of CDR1as in cancer.
In summary, findings above indicate that circRNAs are
potentially involved in cancer initiation and progression.
Certain circRNAs, such as cir-ITCH, play roles in more
than one type of cancers. However, most research cited
above lack the clear demonstration of the molecular
mechanism, and further insights into their association
with cancer would be warranted. Thus, clinical implica-
tions of the circRNAs as new clinical diagnostic and
prognostic markers need further studies.
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Possible mechanisms of circRNAs in cancer
ceRNA
The competitive endogenous RNAs (ceRNAs) contain
shared MREs, such as mRNAs, pseudogenes, and long
noncoding RNAs (lncRNAs), and can compete for
miRNA binding [41]. It is known that miRNAs have
been shown to be involved in nearly all aspects of cellu-
lar functions [42] and play important roles in disease
initiation and progression, especially in cancers [43, 44].
In view of circRNA-binding miRNAs to regulate their
targets, circRNAs may be involved in various cancers
with miRNAs. For example, CDR1as is known highly
expressed and has over 60 binding sites for miR-7 [45].
Emerging evidence indicates that miR-7 can directly
downregulate cancerigenic factors, including epidermal
growth factor receptor (EGFR) [46], P21-activated
kinase-1 (Pak1) [47], insulin receptor substrate-1 (IRS-1)
[48], phosphoinositide 3-kinase catalytic subunit delta
(PIK3CD) [49], and mammalian target of rapamycin
(mTOR) [35]. Thereby, the CDR1as/miRNA axis is likely
involved in many kinds of cancers. Recently, the first
study to exploit circRNA profiling and circRNA/miRNA
interactions in bladder cancer was reported, and Zhong
et al. determinated the regulatory role of circTCF25-
miR-103a-3p/miR-107-CDK6 axes in bladder cancer
[28]. Another study also found that cir-ITCH is involved
in the regulation of the Wnt/β-catenin signaling pathway
in vivo, as sponge of miR-7, miR-17, miR-20a, and miR-
214 [27, 36].
CircRNA-binding proteins
It has been reported that RNA-binding proteins (RBPs),
such as RNA polymerase II [8], Argonaute [3], and MBL
[50], can bind to circRNAs. In addition, several studies
showed that circRNAs may play a role in the genesis
and development of tumor via binding key proteins as-
sociated with cell proliferation, metastasis, and apop-
tosis. Wu et al. demonstrated that ectopic expression of
the circular RNA circ-Foxo3 repressed cell cycle pro-
gression through binding to the cell cycle proteins
cyclin-dependent kinase 2 (CDK2) and cyclin-dependent
kinase inhibitor 1 (or p21), resulting in the formation of
a ternary complex. CDK2 interacts with cyclin A and
cyclin E to facilitate cell cycle entry, while p21 inhibits
these interactions and arrests cell cycle progression [51].
Thus, the formation of circ-Foxo3-p21-CDK2 ternary
complex can inhabit the function of CDK2 and block
cell cycle progression. Because CDK2 is involved in a
variety of cancers, such as breast cancer [52], NSCLC
[53], and CRC [54], it is conceivable that circ-Foxo3
takes a part in cancers above by formation of circ-
Foxo3-p21-CDK2 ternary complex. Circ-Foxo3 can also
bind to proteins ID1, E2F1, FAK, and HIF-1α (HIF1A),
retaining them in the cytoplasm and promoting cardiac
senescence [55]. These findings above indicate that cir-
cRNAs may function as decoys that modify the cellular
destination and/or function of bound partners.
CircRNAs and DNA
DNA replication is the process of producing two identi-
cal replicas from one original DNA molecule. During
DNA replication, circRNAs enriched in the nucleus may
interact with the opposite strand of its genomic DNA
through base-pairing and thus form a DNA-RNA triple
helix affecting DNA replication. It is reported that pRNA
interacts with the target site of the transcription factor
TTF-I, forming a DNA-RNA triplex, which simultan-
eously recruits DNMT3b to repress rRNA expression
[56]. Also, lncRNA ANRASSF1 interacts with a DNA-
forming RNA/DNA hybrid at the transcription start site,
leading to reduced transcription of RAS-association
domain family member 1A (RASSF1A) [57]. These ex-
amples highlight that the interactions between DNA
and nucleus-residing circRNAs in a manner akin to
linear ncRNAs.
Conclusions
It has been decades since circRNAs were discovered.
Though previously thought to be errors in RNA splicing,
circRNAs now have drawn increasing attention of
scientists because of recent improvement of high-
throughput sequencing technologies and bioinformatics
progression. In this review, we regarded natural cir-
cRNAs as an abundant, stable, diverse, and conserved
class of RNA molecules. Based on the location concern-
ing the nearest protein-coding gene, circRNAs can be
classified into three subclasses: exonic circRNAs, ciR-
NAs, and ElciRNAs. According to their functions,
circRNAs can be categorized as sponge, translation, bio-
marker, and regulation molecules. Their roles made
them potential biomarkers of diagnosis and prognosis
and therapeutical targets.
Perspective
Recent advances about circRNAs have been focused on
their biogenesis and functions as miRNA sponges.
Though there has been much progress in circRNAs, the
field of their functions, related mechanisms, and degrad-
ation need to be more investigated. Actually, the field of
circRNAs remains largely unexplored, such as develop-
mental stage-specific expression, turnover, localization,
and degradation. Compared with miRNA and long non-
coding RNAs (lncRNAs), circRNAs are promising clin-
ical diagnostic and prognostic markers for their stable
structure. Among the three subclasses of circular RNAs,
one is cytoplasmatic (circRNA) and two are located in
the nucleus (ciRNAs and EIciRNA) [3–5, 8], suggesting
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that circular RNAs may have a multitude of epigenetic
roles in the cell.
CircRNAs were considered untranslatable, but recent
studies prove that most circRNAs carry open reading
frames, and some of them have IRES elements. With
emerging evidence, more researchers are interested in
this function of circRNAs. Predictably, this will become
the new frontier in research of circRNAs.
Recent report shows for the first time the presence of
abundant circRNAs in exosomes [6]. Exosomes are small
membrane vesicles of endocytic origin secreted by most
cell types [58]. The sorting of circRNAs to exosomes
may be regulated by changes of associated miRNA levels
in producer cells and may transfer biological activity to
recipient cells. Undoubtedly, circRNAs have the poten-
tial to become clinical diagnostic and prognostic
markers, and results above lay the foundation for devel-
opment of circRNAs as a new class of exosome-based
cancer biomarkers and suggest the potential biological
function of exosomal circRNAs.
With the development of technology and research, fur-
ther studies will reveal the functions of the vast majority
of circRNAs in physiological and pathological processes.
Furthermore, circRNAs will play a crucial role in the
diagnosis and treatment of cancer.
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